Last updated on March 2019

Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer


Brief description of study

The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone compared with placebo plus abiraterone and prednisone/prednisolone in participants with metastatic castrate-resistant prostate cancer (mCRPC).

Clinical Study Identifier: NCT03072238

Contact Investigators or Research Sites near you

Start Over

Reference Study ID Number: CO39303 ...

Gangnam Severance Hospital
Seoul, Korea, Republic of
1.92miles
  Connect »

Reference Study ID Number: CO39303 ...

Samsung Medical Center
Seoul, Korea, Republic of
4.3miles
  Connect »

Reference Study ID Number: CO39303 ...

Severance Hospital, Yonsei University Health System; Pharmacy
Seoul, Korea, Republic of
4.3miles
  Connect »

Reference Study ID Number: CO39303 ...

Asan Medical Center
Seoul, Korea, Republic of
4.78miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.